RecruitingNot Applicable

Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection

China200 participantsStarted 2026-03-01

Plain-language summary

This multicenter, ambispective cohort study evaluates the safety and efficacy of trans-arterial Indocyanine Green (ICG) fluorescence-guided laparoscopic liver watershed resection for Hepatocellular Carcinoma (HCC). The study aims to compare the outcomes of the trans-arterial ICG staining approach versus the conventional trans-portal (portal vein) ICG staining approach.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18-80 years.
✓. Postoperative histopathological diagnosis of Hepatocellular Carcinoma (HCC).
✓. Underwent ICG fluorescence-guided laparoscopic anatomical liver resection.
✓. Child-Pugh Class A or B.
✓. ASA score I-III.
✓. ECOG Performance Status 0-2.
✓. No invasion of major vessels (main portal vein/first-order branches, main hepatic vein).
✓. No distant metastasis.

Exclusion criteria

✕. Pathology confirms non-HCC components (e.g., cholangiocarcinoma, combined HCC-ICC) or metastatic liver cancer.
✕. Concomitant other active malignancies.
✕. Preoperative anti-tumor therapy (TACE, ablation, radiotherapy, systemic therapy) or history of prior hepatectomy.
✕. Ruptured tumor.
✕. Conversion to open surgery.
✕. Unclear surgical records regarding ICG staining method.
✕. Intraoperative ICG staining failure (e.g., diffuse staining, unclear boundaries) preventing fluorescence-guided resection.

What they're measuring

Recurrence-Free Survival (RFS)

Timeframe: Up to 18 months post-surgery (assessing the 18-month RFS rate as a key benchmark)

Trial details

NCT IDNCT07295275

SponsorWest China Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-01-01

Contact for this trial

Jiwei Huang Professor

18980606725 huangjiwei@wchscu.cn

View on ClinicalTrials.gov More Liver Cancer trials